Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Shares Bought by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. lifted its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 10.6% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 12,093 shares of the company’s stock after buying an additional 1,162 shares during the quarter. China Universal Asset Management Co. Ltd.’s holdings in Harmony Biosciences were worth $416,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Citigroup Inc. raised its position in Harmony Biosciences by 9.8% during the third quarter. Citigroup Inc. now owns 177,843 shares of the company’s stock worth $7,114,000 after acquiring an additional 15,859 shares during the last quarter. HighTower Advisors LLC raised its position in shares of Harmony Biosciences by 364.0% during the 3rd quarter. HighTower Advisors LLC now owns 79,961 shares of the company’s stock worth $3,199,000 after purchasing an additional 62,729 shares during the last quarter. Quest Partners LLC lifted its stake in Harmony Biosciences by 137.6% in the 3rd quarter. Quest Partners LLC now owns 35,723 shares of the company’s stock valued at $1,429,000 after buying an additional 20,689 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Harmony Biosciences by 68.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 230,428 shares of the company’s stock valued at $9,217,000 after buying an additional 93,622 shares in the last quarter. Finally, CWA Asset Management Group LLC acquired a new stake in Harmony Biosciences during the 3rd quarter valued at $576,000. 86.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Harmony Biosciences news, insider Jeffrey Dierks sold 10,507 shares of the company’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $37.01, for a total transaction of $388,864.07. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Sandip Kapadia sold 1,775 shares of Harmony Biosciences stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $38.05, for a total value of $67,538.75. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 72,452 shares of company stock valued at $2,831,679. 30.80% of the stock is currently owned by company insiders.

Harmony Biosciences Stock Performance

Shares of HRMY stock opened at $38.77 on Monday. The firm has a market capitalization of $2.21 billion, a price-to-earnings ratio of 18.37, a price-to-earnings-growth ratio of 0.51 and a beta of 0.78. The company has a 50 day moving average price of $35.42 and a 200 day moving average price of $35.30. Harmony Biosciences Holdings, Inc. has a one year low of $28.14 and a one year high of $41.61. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on HRMY shares. Needham & Company LLC reissued a “buy” rating and issued a $52.00 price target on shares of Harmony Biosciences in a report on Monday, January 13th. Mizuho upped their target price on shares of Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a report on Thursday, October 10th. Raymond James reiterated an “outperform” rating and set a $40.00 price target on shares of Harmony Biosciences in a report on Thursday, October 10th. HC Wainwright reissued a “buy” rating and set a $75.00 price objective on shares of Harmony Biosciences in a research note on Monday, January 27th. Finally, Cantor Fitzgerald lifted their target price on shares of Harmony Biosciences from $51.00 to $58.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 30th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $55.00.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.